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Background: Central core disease is a congenital myopathy, characterized by presence of central core-like areas in
muscle fibers. Patients have mild or moderate weakness, hypotonia and motor developmental delay. The disease is
caused by mutations in the human ryanodine receptor gene (RYR1), which encodes a calcium-release channel.
Since the RYR1 gene is huge, containing 106 exons, mutation screening has been limited to three ‘hot spots’, with
particular attention to the C-terminal region. Recent next- generation sequencing methods are now identifying
multiple numbers of variants in patients, in which interpretation and phenotype prevision is difficult.
Case presentation: In a Brazilian Caucasian family, clinical, histopathological and molecular analysis identified a
new case of central core disease in a 48-year female. Sanger sequencing of the C-terminal region of the RYR1
gene identified two different missense mutations: c.14256 A > C polymorphism in exon 98 and c.14693 T > C in
exon 102, which have already been described as pathogenic. Trans-position of the 2 mutations was confirmed
because patient’s daughter, mother and sister carried only the exon 98’s mutation, a synonymous variant that was
subsequently found in the frequency of 013–0,05 of alleles. Further next generation sequencing study of the whole
RYR1 gene in the patient revealed the presence of additional 5 common silent polymorphisms in homozygosis and
8 polymorphisms in heterozygosis.
Conclusions: Considering that patient’s relatives showed no pathologic phenotype, and the phenotype presented
by the patient is within the range observed in other central core disease patients with the same mutation, it was
concluded that the c.14256 A > C polymorphism alone is not responsible for disease, and the associated additional
silent polymorphisms are not acting as modifiers of the primary pathogenic mutation in the affected patient. The
case described above illustrates the present reality where new methods for wide genome screening are becoming
more accessible and able to identify a great variety of mutations and polymorphisms of unknown function in
patients and their families.
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Core myopathies is a group of clinically and genetically
heterogeneous congenital myopathies with focally re-
duced oxidative activity visualized on muscle biopsy as
their common defining histopathological feature [1].
These areas, defined as cores, can be single or multiple,
central or eccentric and run through a large area by lon-
gitudinal muscle fiber axis visualized on muscle biopsy
[2]. The wide range of described terms applied to these
disorders (central cores, minicores, multicores, multi-
minicores) is due to variability of oxidative stain irregu-
larities seen in the histopathological analysis [3].
Central core disease (CCD, Online Mendelian Inherit-
ance of Man #117000) is characterized by the presence
of a central and single core-like area on oxidative stains
[3]. It indicates areas of sarcomeric disorganization and
electron microscopy displays mitochondrial depletion
and variable degrees of degeneration of the contractile
apparatus. Abnormal expression of several sarcomeric
and intermediate filament proteins can be seen by im-
munohistochemical studies [4-6].
CCD is intimately linked to malignant hyperthermia
susceptibility (MHS, Online Mendelian Inheritance of
Man #145600) [7], a skeletal muscle’s pharmacogenetic
disorder that is triggered by administration of inhala-
tional anesthetics and depolarizing muscle relaxants in
susceptible individuals [7,8].
Both conditions have been associated to mutations in
human RYR1 gene (Online Mendelian Inheritance of
Man #180901), located on chromosome 19q13.1. It is a
large gene organized in 106 exons [9] that encodes a cal-
cium (Ca2+) release channel known as the ryanodine re-
ceptor (RYR1) situated on skeletal muscle. The
ryanodine receptor is a huge protein of 5037 amino
acids [10] constituted of four RYR1 560 kDa peptides
and many associated proteins with a total molecular
weight of more than 2,500 kDa.
Currently, more than 200 mutations in RYR1 gene
have been described. Some are exclusively associated
with CCD or other RYR1-related myopathies; others are
related with malignant hyperthermia susceptibility trait,
or even with both conditions concomitantly [3].
The RYR1 mutational spectrum linked with CCD in-
cludes mostly heterozygous dominant missense variants
and minor deletions or duplications [10-13]. RYR1 muta-
tions associated with malignant hyperthermia (MH) and
CCD are grouped in three regions of RYR1 protein or
‘hot spots’: N-terminal (residues p.M1-R614), central (p.
R2163–p.R2458) and C-terminal (p.R4136-p.P4973).
These regions are also entitled domains 1–3, respectively
[14]. Domains 1 and 2 are situated in soluble cytoplas-
mic regions of the protein. Domain 3 is placed in C-
terminus and involves the transmembrane/luminal and
pore-forming area of the channel. It is also where mostof CCD mutations are located [11,15]. Variable geno-
type–phenotype correlations associated with mutations
in RYR1 gene are usually justified by the degree of func-
tional variation within this large protein [3].
Here we present clinical features of a family diagnosed
with central core myopathy, in which the affected index
case, in addition to the causative mutation in the RYR1
gene, also presented several other polymorphisms in this
gene, which apparently are not acting as modifiers of the
primary pathogenic mutation.
Case presentation
The index case, a 48-year-old Caucasian female, was re-
ferred to our service with a history of muscle weakness
since childhood. Her delivery and peri-natal period were
uneventful. She was a hypotonic baby, had delayed mile-
stones and presented congenital dislocation of the hip as
a child. Her present clinical evaluation consisted of mild
facial and proximal muscle weakness, lumbar lordosis
and scoliosis. She had no cardiac abnormalities and no
respiratory complaints. An electromyography exam done
in her childhood showed a myopathic pattern. Serum
creatine kinase activity (CK) was normal.
A muscle biopsy of biceps brachii was performed
under local anesthesia. Histological analysis of hematoxi-
lin/eosin (H&E) staining revealed variation in fiber size,
split fibers, some fibers with membrane debris in its in-
terior and presence of multiple nuclei within the major-
ity of fibers. Myofibrillar ATPase reaction showed a
predominance of type I fibers, and NADH-adenine
dinucleotide-tetrazolium reductase reaction revealed
areas devoid of oxidative activity (cores) in almost all fi-
bers (Figure 1). Normal localization and distribution was
found for all studied muscle proteins: dystrophin, the 4
sarcoglycan, dysferlin, calpain 3, telethonin, and α2-
laminin, excluding several forms of limb-girdle muscular
dystrophies.
For molecular analysis, Sanger sequencing for the C-
terminal region (exons 94 to 106) of the RYR1 gene was
first done in genomic DNA, extracted from peripheral
blood lymphocytes [16], using PCR amplification with
described primers [17]. Sequencing was done using se-
quencing kit (Applied Biosystems®) on an ABI 3730 au-
tomated DNA sequencer (Life Technologies).
Subsequently, next generation sequencing of the whole
RYR1 gene was done using Illumina’s Nextera kits for li-
brary preparation and custom capture of 88 genes in-
volved in neuromuscular disorders. Sequencing was
performed at the Illumina MiSeq sequencer, and variants
were filtered and compared to the control populations
of 1000 Genomes, NIH, and 6500 Exome Sequencing
Project from Washington University.
Molecular analysis of the RYR1 gene showed two dif-
ferent mutations in the patient (II-2): a missense
Figure 1 The pedigree of the family, and mutations identified in each member of the family, and respective eletroferogram of part of
exon 102 and exon 98 of the RYR1 gene illustrating the missense alterations. Histological reactions showing HE, ATPase 4.3 and NADH
staining, and immunohistochemical analysis for dystrophin, γ-SG and telethonin. (Magnification – X200).
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cing alteration p.4752 T > T, and a pathogenic missense
mutation c.14693 T > C in exon 102, which results in
the p.4898 I > T substitution in the protein. The c.14256
A > C mutation was also identified in her daughter (III-
1). To exclude a possible unknown deleterious potential,
we studied the mother (I-2) and sister (II-1) of the index
case, and the same alteration was found in both: in a
homozygous state in the mother, and heterozygous state
in the sister (Figure 1). None of the relatives presented
the pathogenic mutation in exon 102. Additional next
generation sequencing study of the whole RYR1 gene in
the patients revealed, in addition to the c.14693 T > C
and c.14256 A > C mutations, the presence of 5 com-
mon silent polymorphisms in homozygosis and 8 poly-
morphisms in heterozygosis (Table 1).
Discussion
Central core myopathy (CCD) is one of the most com-
mon described congenital myopathies, yet its prevalence
and incidence are still uncertain. A regional study in
England demonstrated a frequency for CCD of 1 in
250.000 individuals [17], while another study in Japan re-
vealed that carrier frequency for heterozygous RYR1 mu-
tations in that population could be as high as 1 in 2000
[13].
Most patients with RYR-related CCD usually have
mild or moderate axial and proximal weakness marked
in the hip girdle, characterized generally in infancy with
hypotonia or in early childhood with motor developmen-
tal delay [3]. Skeletal muscle complications such as con-
genital developmental hip dysplasia, scoliosis and foot
deformities (talipes equinovarus) are quite common, aswell as myalgia, muscle stiffness, and exertional weak-
ness with or without rhabdomyolysis are frequently re-
lated and may be the only exhibiting features. Bulbar
and respiratory muscle involvement is unusual, but has
been seen in the most severe neonatal cases, and sporad-
ically in adults. Still, there can be significant variability
in gravity and age of onset of CCD and marked pheno-
type heterogeneity, frequently within the same family,
has been documented [18-20].
Our patient presented clinical features suggesting a
congenital myopathy with a relatively mild progression.
Histological analysis confirmed the diagnosis of CCD.
Although neither her parents, sister nor daughter pre-
sented similar symptoms, a possible late-onset manifest-
ation, or a very mild weakness raised doubt about the
genetic counseling in this family. The youngest patient’s
daughter could have inherited the mutations and was
still in her reproductive years.
The initial molecular analysis encompassing the C-
terminal region of the RYR1 gene revealed two different
mutations in the patient; one found in exon 102, which
was already described as pathogenic [10], whereas the
mutation in exon 98 has been described as a single nu-
cleotide polymorphism, with allele frequency between
0,87/0,13 and 0,95/0,05, and heterozygosis of 0,22
[21-23]. The c.14693 T > C mutation in exon 102 has
been first described in a large Mexican affected family
[10]. Twenty-one individuals of 35 members were diag-
nosed with CCD after clinical evaluation, and symptoms
ranged from mild to severe, associating this mutation
with a highly variable phenotype of CCD. Affected indi-
viduals presented with at least one of the symptoms con-
sistent with CCD: foetal hypotonia, muscular weakness
Table 1 Variants identified in the RYR1 gene trough NGS sequencing of a panel of 88 muscle genes using MiSeq –
Ilumina panel
AAChange.refGene 6500 exomes 1000 genomes
Homozygouse variants
RYR1:NM_000540:exon7:c.A594G:p.L198L,RYR1:NM_001042723:exon7:c.A594G:p.L198L 0,603029 0,6
RYR1:NM_000540:exon11:c.T1077C:p.A359A,RYR1:NM_001042723:exon11:c.T1077C:p.A359A 0,895202 0,93
RYR1:NM_000540:exon15:c.G1668A:p.S556S,RYR1:NM_001042723:exon15:c.G1668A:p.S556S 0,632093 0,64
RYR1:NM_000540:exon19:c.C2286T:p.P762P,RYR1:NM_001042723:exon19:c.C2286T:p.P762P 0,617023 0,62
RYR1:NM_000540:exon24:c.G2943A:p.T981T,RYR1:NM_001042723:exon24:c.G2943A:p.T981T 0,597092 0,6
Heterozygouse variants
RYR1:NM_000540:exon45:c.C7260T:p.H2420H,RYR1:NM_001042723:exon45:c.C7260T:p.H2420H 0,02914 0,03
RYR1:NM_000540:exon49:c.C7872T:p.R2624R,RYR1:NM_001042723:exon49:c.C7872T:p.R2624R 0,168538 0,16
RYR1:NM_000540:exon50:c.G7977A:p.T2659T,RYR1:NM_001042723:exon50:c.G7977A:p.T2659T 0,319545 0,36
RYR1:NM_000540:exon51:c.T8118C:p.I2706I,RYR1:NM_001042723:exon51:c.T8118C:p.I2706I 0,319775 0,36
RYR1:NM_000540:exon51:c.T8190C:p.D2730D,RYR1:NM_001042723:exon51:c.T8190C:p.D2730D 0,32362 0,37
RYR1:NM_000540:exon53:c.G8337A:p.E2779E,RYR1:NM_001042723:exon53:c.G8337A:p.E2779E 0,308213 0,35
RYR1:NM_000540:exon55:c.T8589C:p.S2863S,RYR1:NM_001042723:exon55:c.T8589C:p.S2863S 0,313624 0,36
RYR1:NM_000540:exon62:c.A9186G:p.P3062P,RYR1:NM_001042723:exon62:c.A9186G:p.P3062P 0,310857 0,35
RYR1:NM_001042723:exon97:c.A14241C:p.T4747T,RYR1:NM_000540:exon98:c.A14256C:p.T4752T 0,108642 0,14
RYR1:NM_001042723:exon101:c.T14678C:p.I4893T,RYR1:NM_000540:exon102:c.T14693C:p.I4898T 0 0
NM_: Accession prefix for RNA and protein products that are mainly derived from GenBank cDNA and EST data and are supported by the RefSeq eukaryotic
curation group. http://www.ncbi.nlm.nih.gov/refseq/about/.
Frequency in the 6500 exomes and1000 genomes.
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weakness, foot deformities, scoliosis and congenital hip
dislocation [10]. Subsequently, this same mutation was
also described in other populations. It was found in 3
patients from Italian and Swiss-Italian families, with
muscle weakness as the main symptom [24] and in two
other families from France and North America, in which
both presented muscular weakness and delayed motor
milestones [15]. In Japan, one patient was identified,
with very severe clinical condition, including decreased
foetal movements, hypotonia, respiratory insufficiency at
birth, delayed milestones, congenital dislocation of the
hip, scoliosis and facial muscle weakness [13]. Consider-
ing the above clinical descriptions, the c.14693 T > C
mutation is compatible both with severe and mild
phenotypes.
As our patient is presenting a relatively benign clinical
course, probably there is no significant association be-
tween her pathogenic mutation and the p.4752 T > T
synonymous polymorphism, nor with any of the other
silencing mutations later identified in her DNA, that
could be acting as a modifier of her phenotype, by af-
fecting transcription, splicing, mRNA transport, and
translation.
Conclusions
As our patient’s phenotype is within the range of other
patients described with the same heterozygous mutation,the associated polymorphisms identified in her DNA ap-
parently are not contributing to worsen her phenotype.
Additionally, since all the tested relatives have only the
p.4752 T > T polymorphism and don’t present any typ-
ical CCD features, it can be inferred that this variant
alone, in a homozygous or heterozygous state is not re-
sponsible for the disease.
The case described above illustrates the present reality
where new methods for wide genome screening are be-
coming more accessible and able to identify a great var-
iety of mutations and polymorphisms in patients and
their families. It is still impossible to tell if this informa-
tion helps making more diagnosis and genotype/pheno-
type associations, or if it turns the diagnostic process
more confusing and complex. It is important to always
have this in mind before reaching to a definite diagnosis
for patients and involved family.
Consent
Written informed consent was obtained from the pa-
tient, her daughter, mother and sister, for genetic testing
and for publication of this Case Report including any ac-
companying images. A copy of the written consent is
available for review by the Editor-in-Chief of this jour-
nal. This study was approved by the Comissão Nacional
de Ética em Pesquisa (CONEP - Brazilian ethics commit-
tee) – University of Sao Paulo and Federal University of
Sao Paulo, under the number 297.008.
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